Álvaro Taus

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido et al. · Journal of Thoracic Oncology · 2022 · 203 citations · Full text

Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer

Israel Cañadas, Federico Rojo, Álvaro Taus et al. · Clinical Cancer Research · 2013 · 135 citations · Full text

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

Manuel Hidalgo, Maria Martinez‐García, Christophe Le Tourneau et al. · Clinical Cancer Research · 2017 · 99 citations

Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade

Carlos Gomez‐Roca, Philippe A. Cassier, Dmitriy Zamarin et al. · Journal for ImmunoTherapy of Cancer · 2022 · 93 citations · Full text

Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer

Max Hardy-Werbin, Pedro Rocha, Oriol Arpí et al. · OncoImmunology · 2019 · 85 citations · Full text